C4 Therapeutics (CCCC) Preferred Stock Liabilities (2019 - 2020)
C4 Therapeutics (CCCC) recorded quarterly Preferred Stock Liabilities of $256.5 million in Q3 2020, up 81.9% quarter-over-quarter from $141.0 million in Q2 2020, and up 25552.0% on a YoY basis from N/an in Q4 2019.
C4 Therapeutics (CCCC) Preferred Stock Liabilities (2019 - 2020) Analysis & Trends
C4 Therapeutics' Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $256.5 million for Q3 2020.
- In Q3 2020, Preferred Stock Liabilities rose 25552.0% year-over-year to $256.5 million; the TTM figure through Sep 2020 stood at $256.5 million (up 25552.0% YoY), while the FY2019 annual figure was $111.0 million, changed N/A from the prior year.
- Preferred Stock Liabilities was $256.5 million for Q3 2020 at C4 Therapeutics, up from $141.0 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $256.5 million in Q3 2020 to a low of $1.0 million in Q3 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | C4 Therapeutics | 520.69 Mn | 285.02 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 256.52 Mn |
| Jun 30, 2020 | 141.03 Mn |
| Dec 31, 2019 | 111.00 Mn |
| Sep 30, 2019 | 1.00 Mn |